Case ReportIndian Journal of Pharmacy PracticeVol. 19 | Issue 3 | pp. 397–402Open access
A Case of Dry Gangrene in an Autoimmune Patient: Diagnostic and Therapeutic Challenges
- 1,
- 1,
- 1,
- 2,
- 1*
- 1 Department of Pharmacy Practice, School of Pharmaceutical Sciences, Shri Guru Ram Rai University, Dehradun, Uttarakhand, INDIA.
- 2 Department of Clinical Immunology and Rheumatology, Shri Guru Ram Rai Institute of Medical and Health Sciences, Dehradun, Uttarakhand, INDIA.
Published in Indian Journal of Pharmacy Practice
Correspondence: Anuj Nautiyal
Department of Pharmacy Practice, School of Pharmaceutical Sciences, Shri Guru Ram Rai University, Dehradun, Uttarakhand, INDIA.
Email: anujnautiyal@rediffmail.com
- Received:
- Oct 6, 2025
- Accepted:
- Jan 28, 2026
- DOI:
- 10.5530/ijopp.20260514
How to cite
Pokhriyal, P., Kumari, M., Kharb, D., Gururani, S., & Nautiyal, A. A Case of Dry Gangrene in an Autoimmune Patient: Diagnostic and Therapeutic Challenges. Indian Journal of Pharmacy Practice, 19(3), 397–402. https://doi.org/10.5530/ijopp.20260514
Abstract
Dry gangrene is a severe complication of vascular insufficiency, often associated with Peripheral Arterial Disease (PAD), diabetes, or autoimmune conditions like Rheumatoid Arthritis (RA). This case report presents a patient with RA and PAD who developed dry gangrene, highlighting the diagnostic and therapeutic challenges in such cases. A 42-year-old female patient presented with fever, joint pain, bluish discoloration, and numbness in the extremities. The patient had a history of hypothyroidism and was previously treated for lower limb thrombosis. Physical examination revealed ischemic changes in the fingers and toes. Laboratory investigations showed elevated rheumatoid factor (74.4 IU/mL), high Anti-Cyclic Citrullinated Peptide (Anti-CCP) levels (>200 RU/mL), and positive Antinuclear Antibodies (ANA). Imaging confirmed peripheral arterial disease, and echocardiography suggested mild cardiac dysfunction. Management involved anticoagulation (apixaban), vasodilators (cilostazol, nifedipine, xantinol nicotinate), and antibiotics (clarithromycin, linezolid) to prevent secondary infections. Supportive therapy included analgesics and neuropathic pain management. The patient responded well to treatment and was discharged with counseling on limb care and lifestyle modifications. This case underscores the importance of early recognition and intervention in autoimmune-related vasculopathy leading to gangrene. A multidisciplinary approach, including rheumatology, vascular medicine, and cardiology, is essential for optimal patient outcomes. This report contributes to the understanding of vascular complications in RA and emphasizes the role of aggressive management in preventing severe ischemic events.
Keywords
Subject
Article metadata
| Title | A Case of Dry Gangrene in an Autoimmune Patient: Diagnostic and Therapeutic Challenges |
|---|---|
| Authors | Parshant Pokhriyal; Muskan Kumari; Damini Kharb; Subodh Gururani; Anuj Nautiyal |
| Affiliations | Department of Pharmacy Practice, School of Pharmaceutical Sciences, Shri Guru Ram Rai University, Dehradun, Uttarakhand, INDIA.; Department of Clinical Immunology and Rheumatology, Shri Guru Ram Rai Institute of Medical and Health Sciences, Dehradun, Uttarakhand, INDIA. |
| Corresponding author | anujnautiyal@rediffmail.com |
| Journal | Indian Journal of Pharmacy Practice |
| Volume / Issue | Vol. 19, Issue 3 |
Also in this issue
- Harmonizing Drug Safety and Data Integrity: A Review on the Integration of Pharmacovigillance and Clinical Data Managementpp. 326–337
- Unlocking Precision: Inorganic Nanoparticles Sparking the Next Revolution in Cancer Theranosticspp. 338–345
- Drug Related Problems in Pediatric Patients: A Pharmacist Led Prospective Interventional Studypp. 346–351
- Effectiveness of Rituximab in Maintaining Remission Status at One Year in Children with Nephrotic Syndrome in A Tertiary Care Hospitalpp. 352–360
- Assessment of Gastrointestinal Toxicity in Head and Neck Cancer (HNCS) Patients Receiving Platinum Compounds Chemotherapy at a Tertiary Care Hospitalpp. 361–366